Novartis’ Kymriah, the first CAR-T cell treatment, was developed to efficiently destroy cancer cells by introducing a receptor gene into T cells that recognizes the CD-19 antigen expressed on the cancer cells of patients with B-cell malignancies (Gill & June, 2015; Maus & June, 2016). The gene discussed is CD19; the disease is cancer.